Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges 
in clinical practice

Radosław Osmański; Maria Litwiniuk; Marcin Mardas; Marta Stelmach-Mardas

doi:10.5114/ceh.2025.151618

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2025
vol. 11

Send email

Copy url:

abstract:

Review paper

Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice

Radosław Osmański

¹

,

Maria Litwiniuk

^{1, 2}

,

Marcin Mardas

³

,

Marta Stelmach-Mardas

⁴

Department of Oncology and Immuno-Oncology, Greater Poland Cancer Centre, Poznan, Poland
Department of Pathology and Cancer Prevention, Poznan University of Medical Sciences, Poznan, Poland
Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Poland
Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Poznan, Poland

Clin Exp HEPATOL 2025; 11, 2: 105-112

DOI: https://doi.org/10.5114/ceh.2025.151618

Online publish date: 2025/06/09

View full text Get citation

PlumX metrics:

The number of patients whose chronic metabolic liver disease leads to the development of hepatocellular carcinoma (HCC) is increasing. In patients with non-alcoholic fatty liver disease (NAFLD), HCC can arise in both cirrhotic and non-cirrhotic livers. This complicates appropriate surveillance and causes HCC to be diagnosed at a more advanced stage. Current therapeutic guidelines do not take into account the etiology of HCC when selecting the type of systemic treatment, as the data on the effectiveness of immunotherapy in HCC caused by metabolic dysfunction associated steatotic liver disease (MASLD) are insufficient and come from post-hoc subgroup analysis in phase 3 trials. In order to improve survival in the group of patients with chronic liver disease and metabolic disorders, it is crucial to use non-pharmacological and pharmacological methods to prevent progression of fatty liver disease, treat comorbidities with modification of cardiometabolic risk factors, and implement effective programs for early detection of HCC.

keywords:

Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice

Radosław Osmański 1 , Maria Litwiniuk 1, 2 , Marcin Mardas 3 , Marta Stelmach-Mardas 4

HCC, MASLD, NAFLD, metabolic disorders, immunotherapy

Radosław Osmański

¹

,

Maria Litwiniuk

^{1, 2}

,

Marcin Mardas

³

,

Marta Stelmach-Mardas

⁴